600,000 Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Acquired by Nantahala Capital Management LLC

Nantahala Capital Management LLC bought a new stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 600,000 shares of the company's stock, valued at approximately $4,470,000. Nantahala Capital Management LLC owned approximately 0.88% of EyePoint Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Adage Capital Partners GP L.L.C. grew its position in shares of EyePoint Pharmaceuticals by 51.7% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company's stock valued at $42,838,000 after purchasing an additional 1,958,580 shares in the last quarter. Franklin Resources Inc. grew its holdings in EyePoint Pharmaceuticals by 3.1% during the 4th quarter. Franklin Resources Inc. now owns 4,137,567 shares of the company's stock valued at $30,825,000 after buying an additional 125,519 shares in the last quarter. Vanguard Group Inc. increased its stake in EyePoint Pharmaceuticals by 24.8% in the 4th quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company's stock worth $28,334,000 after acquiring an additional 755,045 shares during the last quarter. Federated Hermes Inc. increased its stake in EyePoint Pharmaceuticals by 92.7% in the 4th quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company's stock worth $27,620,000 after acquiring an additional 1,783,765 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of EyePoint Pharmaceuticals by 28.3% during the 4th quarter. Geode Capital Management LLC now owns 1,538,902 shares of the company's stock worth $11,467,000 after acquiring an additional 339,846 shares in the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Chardan Capital reaffirmed a "buy" rating and set a $33.00 price target on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. Citigroup started coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $33.00 target price on the stock. HC Wainwright reiterated a "buy" rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Finally, StockNews.com upgraded EyePoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $26.63.

EyePoint Pharmaceuticals Price Performance

Shares of NASDAQ:EYPT traded up $0.17 during trading hours on Friday, hitting $7.30. 690,968 shares of the company's stock traded hands, compared to its average volume of 879,755. The business has a fifty day moving average price of $6.00 and a 200-day moving average price of $7.68. EyePoint Pharmaceuticals, Inc. has a 1 year low of $3.91 and a 1 year high of $21.26. The firm has a market capitalization of $502.32 million, a P/E ratio of -3.65 and a beta of 1.39.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The business had revenue of $11.60 million during the quarter, compared to the consensus estimate of $11.02 million. As a group, equities analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.